Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Conditions
- Endometrial Endometrioid Adenocarcinoma
- Endometrial Mixed Cell Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Endometrial Undifferentiated Carcinoma
- Metastatic Endometrioid Adenocarcinoma
- Recurrent Uterine Corpus Cancer
Interventions
- DRUG: Copanlisib
- OTHER: Laboratory Biomarker Analysis
Sponsor
NRG Oncology
Collaborators